ARK Genomic Revolution ETF Price & Performance (ARKG)

Cathie Wood's Ark Invest executed notable trades on March 21, 2025, purchasing over 68,000 shares of Iridium Communications and 243,300 shares of Pacific Biosciences. The transactions reflect Ark's continued interest in disruptive technologies, with a combined value exceeding $2.2 million. Simultaneously, Ark offloaded positions in Illumina and Amgen.1

Cathie Wood's flagship ARK Innovation ETF (ARKK) saw inflows of $277.3 million on March 13, 2025, reversing a six-month outflow trend. Despite a 21.5% loss in the past month, this surge in investor confidence highlights optimism in ARKK's tech-focused strategy, even as major holdings like Tesla and Coinbase face market pressures.2

Ark Invest purchased over 400,000 shares of Tempus AI in February 2025, despite a 15% drop in the stock following mixed earnings. The move underscores Cathie Wood's confidence in the AI healthcare firm’s long-term potential. Tempus now represents significant weightings in both ARKK and ARKG funds.3